skip to main content

Welcome to Evgen Pharma

Evgen is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evgen Pharma Image Strategy


Evgen has a clear strategy for driving shareholder value from its technology

Read more

Evgen Pharma Image History


Evgen has attracted a highly experienced commercial, scientific and advisory team

Read more

Evgen Pharma Image Organisation


Founded in 2007, Evgen has evolved quickly into a clinical stage company

Read more


Evgen is a privately held company owned by its management team, venture capital investors and private individuals. Its largest shareholders are the North West Fund for Biomedical and EV Group.

Find out more


Our clinical pipeline is based on our proprietary Sulforadex® platform technology. Phase I studies have been successfully completed and we are progressing three clinical programmes into Phase II. The three programmes - targeting prostate cancer, breast cancer and subarachnoid haemorrhage – benefit from a substantial body of academic scientific data.

Prostate cancer: a market opportunity in low grade disease

Over 1 million men are diagnosed with prostate cancer every year. Clinical progress has focused on advanced disease but early stage treatment could defer or prevent surgery.

Read more

Breast cancer: the biggest cause of cancer death in women

With more than 1.5 million diagnoses each year worldwide, the successful treatment of breast cancer remains a top priority for medics and pharmaceutical companies alike.

Read more

Subarachnoid haemorrhage (SAH): a recognised orphan indication

SAH accounts for one in every 20 strokes in the UK but during the past two decades no significant clinical advances have been made to combat the condition.

Read more


Stabilisation technology in Sulforadex® means that sulforaphane can be delivered as a stable active in an oral pharmaceutical product.

Find out more